Qube Research & Technologies (QRT)
ACRS icon

Qube Research & Technologies (QRT)’s Aclaris Therapeutics ACRS Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$729K Sell
194,510
-252,665
-57% -$853K ﹤0.01% 2622
2025
Q4 		$1.35M Sell
447,175
-97,585
-18% -$247K ﹤0.01% 2431
2025
Q3 		$1.04M Buy
544,760
+35,410
+7% +$61.7K ﹤0.01% 2496
2025
Q2 		$723K Sell
509,350
-841,470
-62% -$1.14M ﹤0.01% 2575
2025
Q1 		$2.07M Buy
1,350,820
+735,737
+120% +$1.57M ﹤0.01% 1942
2024
Q4 		$1.53M Buy
615,083
+322,238
+110% +$802K ﹤0.01% 1989
2024
Q3 		$337K Sell
292,845
-647,907
-69% -$795K ﹤0.01% 2392
2024
Q2 		$1.03M Sell
940,752
-271,508
-22% -$319K ﹤0.01% 1873
2024
Q1 		$1.5M Sell
1,212,260
-467,645
-28% -$558K ﹤0.01% 1912
2023
Q4 		$1.76M Buy
+1,679,905
New +$5.13M ﹤0.01% 1589
2021
Q1 		– Sell
-16,992
Closed -$110K – 1866
2020
Q4 		$110K Buy
+16,992
New +$71.7K ﹤0.01% 1631

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ACRS Position: Q1 2026 in Review

Qube Research & Technologies (QRT) reduced its Aclaris Therapeutics (ACRS) stake by 57% in Q1 2026, selling an estimated $853K and leaving 194,510 shares worth $729K. The position accounts for ﹤0.01% of the portfolio, ranked #2622.

Qube Research & Technologies (QRT) first reported a position in ACRS in Q4 2020 and has held it in 11 quarters since. The position peaked at $2.07M in Q1 2025. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Qube Research & Technologies (QRT) held 194,510 shares of Aclaris Therapeutics worth $729K as of Q1 2026.
  • Qube Research & Technologies (QRT) sold 252,665 Aclaris Therapeutics shares in Q1 2026, an estimated $853K.
  • Aclaris Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #2622 holding.
  • Qube Research & Technologies (QRT) first reported a position in Aclaris Therapeutics in Q4 2020 and has held it in 11 quarters since.
  • Qube Research & Technologies (QRT)'s Aclaris Therapeutics position peaked at $2.07M in Q1 2025.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.